Skip to main content

Table 1 Number of patients (%) for patient and tumor characteristics of each treatment group

From: Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma

Characteristics Complete TACE Incomplete TACE P-value
Curative Tx SABR Non-curative Tx
Age      0.622
 Range (median, years) 41–83 (55) 35–77 (60) 42–74 (59) 24–84 (59)  
Sex      0.426
 Male 14 (58) 33 (70) 29 (78) 49 (70)  
 Female 10 (42) 14 (30) 8 (22) 21 (30)  
BCLC stage      0.135
 0 9 (38) 8 (17) 6 (16) 12 (17)  
 A 15 (63) 39 (83) 31 (84) 58 (83)  
CTP score      0.040
 5 18 (75) 42 (89) 26 (70) 47 (67)  
 6 3 (13) 5 (11) 7 (19) 16 (23)  
 7 3 (13) 0 ( 0) 4 (11) 7 (10)  
Tumor size      0.073
 Range (median, cm) 0.5–8 (2.1) 1–8 (2.8) 0.8–10 (3.4) 0.5–10 (3.8)  
 0.1–3.0 cm 19 (79) 32 (68) 18 (49) 36 (51)  
 3.1–10.0 cm 5 (21) 15 (32) 19 (51) 34 (49)  
  1. Abbreviations: TACE transcatheter arterial chemoembolization, Tx treatment, SABR stereotactic ablative radiotherapy, BCLC Barcelona Clinic Liver Cancer, CTP Child-Turcotte-Pugh